Peritoneal fibrosis (PF) is invariably observed in patients undergoing long-term peritoneal dialysis (PD). The condition is thought to occur in response to a variety of insults, including bioincompatible dialysates (acidic solution, high glucose, glucose degradation products, or a combination), peritonitis, uremia, and chronic inflammation. Recently, the pathophysiologic mechanisms that contribute to the fibrosing process have been intensively studied. Transforming growth factor-β has been shown to be a key mediator of PF. Loss of the mesothelial cell layer has been identified in several studies and shown to correlate with submesothelial thickening and vasculopathy. An association has also been identified between increased submesothelial thickness in the peritoneal membrane and increased solute transport, suggesting a relationship between PF and loss of ultrafiltration capacity. Thus, to maintain long-term PD and improve quality of life for patients, it is important to develop interventions for prevention and treatment of PF.
Several strategies for peritoneal fibrosis intervention have been reported, including developing biocompatible dialysate, targeting mediators responsible for inflammation and fibrosis, and reconstituting the peritoneum using mesothelial or bone marrow–derived cells. Recent experimental trials in animal models and clinical studies are presented in this review.
WilliamsJDCraigKJTopleyNVon RuhlandCFallonMNewmanGR. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol2002; 13:470–9.
2.
PlumJHermannSFusshollerASchoenickeGDonnerARohrbornA. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int2001; 59(Suppl 78):S42–7.
3.
DevuystOTopleyNWilliamsJD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant2002; 17(Suppl 3):12–15.
4.
NaikiYMaedaYMatsuoKYonekawaSSakaguchiMIwamotoI. Involvement of TGF-β signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol2003; 16:95–102.
5.
KangDHHongYSLimHJChoiJHHanDSYoonKI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-β1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int1999; 19:221–30.
6.
MargettsPJKolbMGaltTHoffCMShockleyTRGauldieJ.Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol2001; 12:2029–39.
7.
MoussadEEBrigstockDR. Connective tissue growth factor: what's in a name?Mol Genet Metab2000; 71:276–92.
8.
WitowskiJWisniewskaJKorybalskaKBenderTOBreborowiczAGahlGM. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol2001; 12:2434–41.
9.
KimYSKimBCSongCYHongHKMoonKCLeeHS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-β. J Lab Clin Med2001; 138:59–68.
10.
HondaKNittaKHoritaSYamuraWNiheiHNagaiR. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant1999; 14:1541–9.
11.
CombetSFerrierMLVan LandschootMStoenoiuMMoulinPMiyataT. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol2001; 12:2146–57.
12.
EddyAA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol2002; 283:F209–20.
13.
RougierJPGuiaSHagegeJNguyenGRoncoPM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-β1. Kidney Int1998; 54:87–98.
14.
NohHHaHYuMRKimYOKimJHLeeHB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int2005; 25:38–47.
15.
KiribayashiKMasakiTNaitoTOgawaTItoTYoriokaN. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int2005; 67:1126–35.
16.
WilliamsJDTopleyNCraigKJMackenzieRKPischetsriederMLageC. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int2004; 66:408–18.
17.
BajoMASelgasRCastroMAdel PesoGDiazCSanchez– TomeroJA. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int2000; 20:742–7.
18.
le PooleCYWeltenAGWeijmerMCValentijnRMvan IttersumFJter WeePM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int2005; 25(Suppl 3):S64–8.
19.
YungSLiuZHLaiKNLiLSChanTM. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor β1 and fibronectin by human peritoneal mesothelial cells. Perit Dial Int2001; 21(Suppl 3):S41–7.
20.
ChanTMLeungJKTsangRCLiuZHLiLSYungS.Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int2003; 64: 519–33.
21.
HungKYHuangJWChenCTLeePHTsaiT J. Pentoxifylline modulates intracellular signalling of TGF-β in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant2003; 18:670–6.
22.
FangCCYenCJChenYMChuTSLinMTYangJY. Diltiazem suppresses collagen synthesis and IL-1β–induced TGF-β1 production on human peritoneal mesothelial cells. Nephrol Dial Transplant2006; 21:1340–7.
23.
HungKYChenCTHuangJWLeePHTsaiTJHsiehBS. Dipyridamole inhibits TGF-β –induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int2001; 60:1249–57.
24.
MargettsPJGyorffySKolbMYuLHoffCMHolmesCJ. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol2002; 13:721–8.
25.
FukuyamaJIchikawaKMiyazawaKHamanoSShibataNUjiieA.Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol1996; 70:321–7.
26.
FukuyamaJIchikawaKHamanoSShibataN.Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol1996; 318:327–32.
27.
KyudenYItoTMasakiTYoriokaNKohnoN.TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int2005; 25:483–91.
28.
DumanSGunalAISenSAsciGOzkahyaMTerziogluE. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?Perit Dial Int2001; 21:219–24.
29.
DumanSSenSDumanCOreopoulosDG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs2005; 28:156–63.
30.
GiriSNBiringINguyenTWangOHydeDM. Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide2002; 7:109–18.
31.
ZareieMTangelderGJter WeePMHekkingLHvan LambalgenAAKeuningED. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant2005; 20:2783–92.
32.
KakutaTTanakaRSatohYIzuharaYInagiRNangakuM. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int2005; 68:1326–36.
33.
IoHHamadaCRoYItoYHiraharaITominoY.Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int2004; 65:1927–36.
34.
YoshioYMiyazakiMAbeKNishinoTFurusuAMizutaY. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int2004; 66:1677–85.
35.
Di PaoloNSacchiGVanniLCorazziSTerranaBRossiP. Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron1991; 57:323–31.
36.
HekkingLHHarveyVSHavenithCEvan den BornJBeelenRHJackmanRW. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis. Perit Dial Int2003; 23:323–30.
37.
NagyJAShockleyTRMasseEMHarveyVSHoffCMJackmanRW. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther1995; 2:402–10.
